News

Evkeeza is now approved for the treatment of homozygous familial hypercholesterolemia (HoFH) in patients as young as 1 year old.

Recent analysis reveals Medicaid's impact on mortality, highlighting the need for diverse research methods to inform policy changes effectively.

Tavapadon is an investigational, novel, once-daily treatment option for Parkinson’s disease, which currently affects more than 1 million Americans.

The expiration of ACA tax credits threatens $32 billion in healthcare revenue, risking coverage for millions and increasing uncompensated care costs.

MedImpact launches a performance-driven PMPM pricing model, enhancing cost predictability and accountability for health plans amid rising pharmacy expenses.

Today’s announcement builds on a previous announcement of more than 40% off the Eliquis list price, a direct-to-consumer program that began earlier this month.

FDA rejects Rexulti's approval for PTSD treatment, citing insufficient evidence of effectiveness in combination with sertraline. Otsuka and Lundbeck announced they are planning next steps.

Robert Gamble, CEO of RxBenefits, shares how Illuminate Rx does specialty, plus the areas they will continue to innovate on.

The FDA letter requested that a technical information update be included in the Chemistry Manufacturing and Controls (CMC) module of the sNDA.

Carbapenemase-producing Enterobacterales (CRE) surge in the U.S., with New Delhi metallo-β-lactamase (NDM) becoming a major public health threat.

The complete response letter was issued by the FDA during a routine inspection of a third-party fill-finish facility, not because of an issue with apitegromab.

Data quality issues and increased rates of claim denials provide opportunities for artificial intelligence to make improvements, according to a recent survey by Experian Health.

Employers adapt healthcare strategies amid rising costs, focusing on specialty drugs and chronic conditions to enhance employee wellbeing and control expenses.

Brian K. Lee, Ph.D., of Drexel University Dornsife School of Public Health, says that despite the fact that some studies suggest there is link between acetaminophen use during pregnancy and neurodevelopmental disorders, there is a lack of evidence to support that conclusion.

Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster administration and broader access to immunotherapy.

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s disease.

Here’s what you missed this week on Managed Healthcare Executive.

Opzelura gains FDA approval as the first topical JAK inhibitor for children with atopic dermatitis, offering a steroid-free treatment option.

On the second day of its meeting, the Advisory Committee on Immunization Practices (ACIP) postponed a decision on giving hepatitis B vaccines at birth and revoted against coverage of the combined MMRV vaccine under the Vaccines for Children program.

RxBenefits is aiming to fill gaps in the PBM market with a new option for self-funded employers and brokers, called Illuminate Rx.

This spray formulation of bumetanide demonstrated a 33% faster absorption rate than oral bumetanide, according to clinical trial data.

The Advisory Committee on Immunization Practices pulled back its recommendation concerning a shot that combines the measles, mumps and rubella vaccine with one for varicella. A vote on the hepatitis B vaccine at birth was postponed until tomorrow.

Nearly half of women experience hormone-driven vocal changes during menopause, which may alter voice quality and affect those in voice-reliant careers, a new review finds.

Former CDC director Susan Monarez, Ph.D., testified at today’s Senate hearing that HHS Secretary Robert F. Kennedy Jr. directed her to fire scientists for refusing to rubber-stamp vaccine changes.

RxBenefits has released Illuminate Rx, a new PBM aiming to fill gaps in the current PBM market, according to Robert Gamble, CEO of RxBenefits.

Advances in HIV medication, its window of detection and its transmission risk within the last decade have led to an updated version of the HIV exposure protocol for healthcare personnel.

Elevated levels of the gut hormone GLP-1 and its receptor may worsen brain inflammation and trigger severe symptoms in patients with neuromyelitis optica spectrum disorder (NMOSD), suggesting GLP-1 drugs could pose risks for this rare autoimmune disease.

Results show that GLP-1s may address rheumatoid arthritis (RA) symptoms, independent of established weight loss and cardiac benefits, by reducing the systemic, chronic inflammation associated with RA.